Bhumi Pharmaceuticals Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Bhumi Pharmaceuticals Pharmaceutical Export Portfolio Dataset — 2 Products, $1.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Bhumi Pharmaceuticals — Pharmaceutical Exporter Profile (2026) | 2 Products, $1.5M Trade | TransData Nexus

Bhumi Pharmaceuticals

Indian Pharmaceutical Exporter · Antibiotics Specialist · $1.5M Total Trade · DGFT Verified

Bhumi Pharmaceuticals is an Indian pharmaceutical exporter with a total trade value of $1.5M across 2 products in 2 therapeutic categories. Based on 50 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ampicillin ($1.3M), Mebendazole ($158.3K), .

Bhumi Pharmaceuticals — Export Portfolio & Destination Treemap

Bhumi Pharmaceuticals pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Bhumi Pharmaceuticals? — Company Overview & Market Position

Established in 2013, Bhumi Pharmaceuticals is a prominent manufacturer and exporter of pharmaceutical products based in Vadodara, Gujarat, India. The company specializes in a diverse range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Operating under the leadership of CEO Prakash Kachhwani, Bhumi Pharmaceuticals has grown to employ approximately 100 professionals. The company is registered under the Corporate Identification Number (CIN) U51909GJ2021PTC128070 and maintains an authorized capital of ₹0.10 million with a paid-up capital of ₹0.10 million. Bhumi Pharmaceuticals' annual turnover is reported to be between ₹25 to ₹100 crore, reflecting its significant presence in the pharmaceutical industry. The company's official website is www.bhumipharma.com, providing comprehensive information about its products and services.

What Does Bhumi Pharmaceuticals Export? — Product Portfolio Analysis

Top Products by Export Value

1Ampicillin$1.3M 2Mebendazole

Product Portfolio — Top 2 by Export Value

Bhumi Pharmaceuticals exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ampicillin	Antibiotics	$1.3M	26	0.9%	9
2	Mebendazole	Antimalarial & Antiparasitic	$158.3K	24	1.2%	15

Bhumi Pharmaceuticals exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $1.5M. The top category is Antibiotics (89.1% of portfolio), followed by Antimalarial & Antiparasitic (10.9%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Bhumi Pharmaceuticals — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Bhumi Pharmaceuticals operates a state-of-the-art manufacturing facility located in Vadodara, Gujarat. The plant is equipped with advanced machinery and adheres to stringent quality control measures to ensure the production of high-quality pharmaceutical formulations. The facility's capacity and specific specializations are not publicly disclosed; however, the company's diverse product portfolio indicates a versatile manufacturing capability. The plant's adherence to Good Manufacturing Practices (GMP) is evidenced by its WHO-GMP certification, ensuring compliance with international quality standards.

3Key Leadership

The leadership team at Bhumi Pharmaceuticals is headed by CEO Prakash Kachhwani, who has been instrumental in steering the company towards growth and innovation. Under his guidance, the company has expanded its product range and strengthened its position in both domestic and international markets. The company's leadership also includes directors such as Kanchan Prakash Kachhwani, who contribute to strategic decision-making and operational excellence. The management team's expertise and commitment to quality have been pivotal in establishing Bhumi Pharmaceuticals as a trusted name in the pharmaceutical industry.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Bhumi Pharmaceuticals Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Bhumi Pharmaceuticals has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained WHO-GMP certification, which is a prerequisite for exporting pharmaceutical products to these regions. This certification demonstrates Bhumi Pharmaceuticals' commitment to maintaining high manufacturing standards and quality assurance processes. While specific regulatory filings and approvals in these markets are not publicly disclosed, the WHO-GMP certification enhances the company's credibility and facilitates market access. The company's focus on compliance with international standards positions it favorably for potential partnerships and market entry in these regulated regions.

2Emerging Markets

Bhumi Pharmaceuticals has strategically targeted emerging markets in Africa, Latin America, and Southeast Asia to diversify its export portfolio. The company's WHO-GMP certification plays a crucial role in facilitating access to these markets, as it is recognized by regulatory authorities in these regions. By leveraging this certification, Bhumi Pharmaceuticals can navigate the regulatory landscapes of emerging markets more effectively, ensuring compliance and building trust with local stakeholders. The company's proactive approach to expanding its footprint in these regions reflects its commitment to global growth and market diversification.

Bhumi Pharmaceuticals — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Bhumi Pharmaceuticals' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's WHO-GMP certification indicates adherence to international manufacturing standards, which is a positive indicator for potential FDA evaluations. However, without publicly accessible records, a comprehensive assessment of the company's FDA status cannot be conducted. Prospective partners and stakeholders are advised to engage directly with Bhumi Pharmaceuticals to obtain detailed information regarding FDA approvals and compliance.

2WHO & EU GMP

Bhumi Pharmaceuticals holds WHO-GMP certification, affirming its compliance with international manufacturing standards. This certification is recognized by the European Directorate for the Quality of Medicines & HealthCare (EDQM), facilitating potential market access within the European Union. While specific EU GMP certificates are not publicly disclosed, the WHO-GMP certification serves as a foundational quality assurance credential. The company's commitment to maintaining high manufacturing standards positions it favorably for partnerships and market entry in regions that recognize WHO-GMP certification.

CDSCO & Indian Regulatory

Bhumi Pharmaceuticals — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the pharmaceutical export sector, Bhumi Pharmaceuticals faces competition from both domestic and international manufacturers. Key competitors include established Indian pharmaceutical companies with extensive product portfolios and global distribution networks. While specific market share data is not publicly available, Bhumi Pharmaceuticals' focus on high-demand therapeutic areas such as antibiotics and antimalarial drugs positions it strategically in the market. The company's WHO-GMP certification and commitment to quality manufacturing standards further differentiate it from competitors, potentially providing a competitive edge in securing partnerships and market access.

2Key Differentiators

Bhumi Pharmaceuticals' key differentiators include its WHO-GMP certification, which underscores its adherence to international manufacturing standards, and its focus on high-demand therapeutic areas such as antibiotics and antimalarial drugs. The company's commitment to quality assurance and its strategic expansion into emerging markets further enhance its competitive position. These factors collectively contribute to Bhumi Pharmaceuticals' reputation as a reliable and quality-focused pharmaceutical exporter.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Bhumi Pharmaceuticals as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Bhumi Pharmaceuticals has demonstrated a consistent track record in pharmaceutical exports, with a total export value of $1.5 million USD across 50 shipments. The company's focus on high-demand therapeutic areas such as antibiotics and antimalarial drugs indicates a strategic approach to product selection. The absence of publicly available records indicating regulatory issues, such as Form 483 observations or warning letters, suggests a reliable and compliant manufacturing process. These factors collectively indicate that Bhumi Pharmaceuticals is a dependable supplier in the pharmaceutical export sector.

2Certifications to Verify

Importers should verify the following certifications to ensure compliance and quality standards:

WHO-GMP Certification: Confirms adherence to international manufacturing practices. Verification can be obtained by contacting Bhumi Pharmaceuticals directly or through the World Health Organization's official channels.

EU GMP Certification: Indicates compliance with European manufacturing standards. Verification can be conducted by contacting Bhumi Pharmaceuticals or the European Medicines Agency.

Frequently Asked Questions — Bhumi Pharmaceuticals

How many pharmaceutical products does Bhumi Pharmaceuticals export from India?

Bhumi Pharmaceuticals exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Ampicillin ($1.3M), Mebendazole ($158.3K). Total export value is $1.5M.

What is Bhumi Pharmaceuticals's total pharmaceutical export value?

Bhumi Pharmaceuticals's total pharmaceutical export value is $1.5M, based on 50 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Bhumi Pharmaceuticals cover?

Bhumi Pharmaceuticals exports across 2 therapeutic categories. The largest are Antibiotics (89.1%, 1 products), Antimalarial & Antiparasitic (10.9%, 1 products).

Get Full Bhumi Pharmaceuticals Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.